Potentiation of 5-fluorouracil encapsulated in zeolites as drug delivery systems for in vitro models of colorectal carcinoma by Vilaça, Natália et al.
 1 
Potentiation of 5-fluorouracil encapsulated in zeolites as drug 1 
delivery systems for in vitro models of colorectal carcinoma 2 
 3 
Natália Vilaça,
a
 Ricardo Amorim,
b,c
 Ana F. Machado,
a
 Pier Parpot,
a
 Manuel F.R. Pereira,
d
 4 
Mariana Sardo,
e
 João Rocha,
e
 António M. Fonseca,
a 
Isabel C. Neves*
a
 and Fátima Baltazar*
b,c 
5 
 6 
 7 
a
Centre of Chemistry, Chemistry Department, University of Minho, Campus de Gualtar, 8 
4710-057 Braga, Portugal - E-mail: (ineves@quimica.uminho.pt) 9 
b
Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of 10 
Minho, Campus Gualtar, Braga, Portugal - E-mail: (fbaltazar@ecsaude.uminho.pt) 11 
cICVS/3B’s - PT Government Associate Laboratory, Braga/Guimarães, Portugal 12 
d
Laboratory of Catalysis and Materials (LCM), Associate Laboratory LSRE/LCM, Faculdade 13 
de Engenharia, Universidade do Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal 14 
e
CICECO – Chemistry Department, University of Aveiro, Campus de Santiago, 3810-193 15 
Aveiro, Portugal 16 
 17 
 18 
ABSTRACT  19 
The studies of potentiation of 5-fluorouracil (5-FU), a traditional drug used in the treatment of 20 
several cancers, including colorectal (CRC), were carried out with zeolites Faujasite in the 21 
sodium form, with different particle sizes (NaY, 700 nm and nanoNaY, 150 nm) and Linde 22 
type L in the potassium form (LTL) with a particle size of 80 nm. 5-FU was loaded into 23 
zeolites by liquid-phase adsorption. Characterization by spectroscopic techniques (FTIR, 
1
H 24 
NMR and 
13
C and 
27
Al solid-state MAS NMR), chemical analysis, thermal analysis (TGA), 25 
nitrogen adsorption isotherms and scanning electron microscopy (SEM), demonstrated the 26 
 2 
successful loading of 5-FU into the zeolite hosts. In vitro drug release studies (PBS buffer pH 27 
7.4, 37 ºC) revealed the release of 80-90% of 5-FU in the first 10 min. To ascertain the drug 28 
release kinetics, the release profiles were fitted to zero-order, first-order, Higuchi, Hixson-29 
Crowell, Korsmeyer-Peppas and Weibull kinetic models. The in vitro dissolution from the 30 
drug delivery systems (DDS) was explained by the Weibull model. The DDS efficacy was 31 
evaluated using two human colorectal carcinoma cell lines, HCT-15 and RKO. Unloaded 32 
zeolites presented no toxicity to both cancer cells, while all DDS allowed an important 33 
potentiation of the 5-FU effect on the cell viability. Immunofluorescence studies provided 34 
evidence for zeolite-cell internalization.  35 
 36 
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1. Introduction  40 
Colorectal carcinoma (CRC) is one of the most common types of cancer in industrialized 41 
countries, slightly more prevalent in men than women [1]. Generally, the treatment of CRC 42 
includes surgery, radiotherapy and/or chemotherapy. The treatment design depends, however, 43 
largely on the cancer stage. Although for patients with an early-stage disease, surgery gives a 44 
relatively good prognosis; patients in a more advanced disease stage often require adjuvant 45 
chemotherapy to reduce cancer and the high risk of recurrence [2-4]. 46 
5-Fluorouracil (5-FU) has been in use for about 50 years [5], being one of the most effective 47 
chemotherapeutic agents in the treatment of CRC, stomach, breast, and head & neck cancers 48 
[6,7]. Despite the progress made with the introduction of new cytotoxic agents and medical 49 
practices, the survival rates of CRC patients changed little over the past 20 years [8-12], 50 
justifying the need for more effective therapies.  51 
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Therapy with classical drugs such as 5-FU, has important toxic side effects. Thus, 52 
encapsulation in sustained delivery systems may contribute to reduce these side effects and 53 
maybe allow oral administration. 5-FU is administered intravenously due to its variable 54 
gastrointestinal absorption and rapid degradation [13,14].
 
There are several advantages to oral 55 
drug administration, including patient’s convenience and the reduced costs associated with 56 
drug preparation and administration [4]. The efficacy of 5-FU therapy may also be enhanced 57 
and its toxicity diminished by association with delivery systems that selectively convey this 58 
active agent while, at the same time, reduce its toxicity [15]. Moreover, encapsulation may 59 
allow drugs to be released in a controlled way to the cancer area, preventing degradation of 60 
the anticancer drug [4,15,16].  61 
Several recent studies showed that the potential of zeolites in medical applications is due to 62 
their structural properties and stability in biological environments [17,18]. Zeolites have also 63 
been explored as suitable hosts for the encapsulation of drug molecules, in search for efficient 64 
DDS. Both zeolites and drugs have been administrated simultaneously to a patient without 65 
loss of the individual pharmacological effect of the drugs [17-28]. 66 
Zeolites are solid hydrated crystalline materials with frameworks comprising silicon, 67 
aluminum and oxygen and featuring nano-channels and cages of regular dimensions [29]. The 68 
pores of zeolites are open to the surrounding medium, thus allowing diffusion of molecules 69 
from the exterior to the interior of the zeolite particle. Zeolites exhibit a large specific surface 70 
area, typically in excess of 400 m
2
 g
-1
, with most of this area being internal (void volume 71 
above 0.10 cm
3
 g
-1
),
 
and are very stable in different media [29].
 
The water molecules within 72 
the cavities are loosely bound and are easily removed upon heating, resulting in a high surface 73 
area and accessible pore volume [29]. 74 
In previous studies we have reported the preparation of DDS based on zeolite structures with 75 
the experimental anticancer drug -cyano-4-hydroxycinnamic acid (CHC) and demonstrated 76 
its efficacy against colorectal carcinoma cells [30,31]. As a continuation of this line of 77 
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research, the anticancer drug 5-FU was encapsulated into two zeolites with diverse 78 
frameworks and particle size. Zeolite L is an aluminosilicate bearing parallel one-dimensional 79 
channels with pore openings of ca. 0.71 nm in diameter, able to host a large variety of small 80 
molecules [32]. Zeolite Y consists of supercages with a diameter of 1.18 nm, sharing a 12-81 
membered ring with an aperture of 0.74 nm [33], suitable to accommodate various 82 
compounds [33-36]. These new DDS were characterized by a range of methods, spectroscopic 83 
techniques (FTIR and 
13
C and 
27
Al solid-state MAS NMR), scanning electron microscopy 84 
(SEM), thermogravimetric analysis (TGA), nitrogen adsorption isotherms and elemental 85 
analysis. The effect of zeolites and DDS was evaluated on HCT-15 and RKO human colon 86 
carcinoma cell viability. Zeolite-cell internalization was also assessed. 87 
 88 
2. Materials and Methods 89 
2.1. Materials  90 
Linde Type L zeolite powder in the potassium form (NanoZeolite LTL, Si/Al = 3.40) with ~ 91 
80 nm average particle size was purchased from NanoScape. Two faujasite zeolites with 92 
different particle sizes were commercially available in the sodium form and as a powder; NaY 93 
zeolite (Si/Al = 2.83, CBV100) was obtained from Zeolyst International and nanoNaY zeolite 94 
(NanoFAU-Y, Si/Al = 2.25) from NanoScape. 5-fluoro-1H-pyrimidine-2,4-dione usually 95 
know as 5-fluorouracil (5-FU) was used as obtained from Sigma-Aldrich (99%). Rhodamine 96 
B was supplied by Merck (≥90%).  97 
2.2. Preparation of 5-FU@zeolites  98 
Loading of 5-FU into zeolites was based on a previously established procedure [30,31]. 99 
Before
 
5-FU loading, the zeolite powders were dehydrated at 120 °C overnight in order to 100 
remove the water from the pores.
 
5-FU loading into the zeolites was achieved by mixing 100 101 
mg of each zeolite with a solution of 5-FU (130 mg, 0.99 mmol) in acetone (15 mL) as a 102 
solvent and was stirred (300 rpm) for 48 h at room temperature. The mixture was filtered and 103 
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the resulting DDS dried in an oven at 60 ºC for 12 h. This temperature is enough to evaporate 104 
the acetone solvent. Throughout the manuscript, the obtained DDS will be referred to as 5-105 
FU@zeolite, where zeolite represents the structure of the zeolite used. Also, preliminary 106 
studies with other solvents in which 5-FU is soluble (ethanol and methanol) were carried out 107 
under the same experimental conditions to which the 5-FU@zeolite samples were submitted. 108 
After preparation of the DDS, these solvents remained adsorbed in the zeolite structures and 109 
are toxic to the cell lines studied. The amount of loaded 5-FU was measured using 110 
thermogravimetric analysis (TGA). In order to evaluate the solvent effect, the zeolites were 111 
prepared with 15 mL of solvent, using the same experimental conditions as the DDS samples.  112 
The cellular location of NaY was monitored by loading this zeolite with Rhodamine B. This 113 
compound was loaded into NaY by stirring (300 rpm, 48h at room temperature) a mixture of 114 
100 mg of zeolite in a solution of Rhodamine B (20 mg, 0.042 mmoles) in acetone (15 mL). 115 
The reaction vessel was lined with foil to protect from light. The mixture was filtered and the 116 
obtained solid (referred to as RB@NaY) was dried at 60 ºC for 12 h.  117 
2.3. Drug release studies of 5-FU@zeolites 118 
Drug release from loaded 5-FU@zeolite samples was studied by HPLC analysis at  = 260 119 
nm. The simulated body fluid was made using known amounts of a buffer solution of sodium 120 
monobasic phosphate and sodium dibasic phosphate (PBS). Known amounts of the DDS were 121 
mixed (10 mg) in 50 mL of PBS solution in order to simulate body fluid at pH 7.4 and 37 °C. 122 
The samples were stirred at ca. 60 rpm and 5 mL aliquots of DDS/PBS were removed at 123 
regular intervals and an equal amount of fresh dissolution medium was added to keep the 124 
volume of mixture constant (50 mL). The aliquots were filtered through a 0.20 µm filter 125 
(Whatman) and analyzed by HPLC. The amount of released 5-FU was calculated using the 126 
equation previously described [36]. Experiments were conducted in triplicate and the values 127 
were averaged. The release studies were carried out for 48 h, corresponding to the time of 128 
contact of DDS with the cells.  129 
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2.4. Cell culture conditions and cell viability assays  130 
HCT-15 and RKO were used in this study as models of human colorectal carcinoma. HCT-15 131 
colon carcinoma cells were maintained in RPMI 1640 medium (Gibco) and RKO colon 132 
carcinoma cells were maintained in DMEM medium (Gibco). Both cell lines were 133 
supplemented with 10% (v/v) fetal bovine serum (FBS) (Gibco, Invitrogen, USA) and 1% 134 
(v/v) penicillin-streptomycin solution (P/S) (Invitrogen, USA) and incubated at 37 °C in a 5% 135 
CO2 humidified atmosphere. Cells were subcultured approximately every three days and 136 
maintained in a log-phase growth. 137 
Cell viability was assessed using the In Vitro Toxicology Assay Kit, Sulforhodamine B based 138 
(Sigma-Aldrich, St. Louis, MO, USA). HCT-15 (7500 cells/100µL/well) and RKO (6000 139 
cells/100µL/well) cells were seeded in 96-well plates and incubated at 37 °C in a 5% CO2 140 
humidiﬁed atmosphere for 24 h. In order to assess the effects of the starting zeolites, 5-FU 141 
and DDS used and cells were incubated with increasing concentrations of the systems in 142 
culture medium. Controls were performed with culture medium alone. After an incubation 143 
period of 48 h, the spent media were removed and the plate wells were washed with 1x 144 
Phosphate-buffered solution, pH 7.4 (PBS). After a fixation step with cold 10% 145 
trichloroacetic acid (TCA), cells were stained with 0.4% Sulforhodamine B and the 146 
incorporated dye was solubilized with Sulforhodamine B solubilization solution (10 mM 147 
Tris). Absorbance was monitored with a microplate reader at 570 nm with a background 148 
absorbance of 655 nm. Cell viability was determined as percentage of viability: (OD 149 
experiment/OD control) x 100 (%). Results are presented as mean ± standard deviation (SD) 150 
of three independent experiments, each in triplicate. One-way ANOVA, followed by Dunnett 151 
post test (Fig. 6 and 7) were used to perform cell viability assay statistical analysis. The 152 
previous tests and 50% growth inhibition (IC50) were determined using the Graphpad Prism 153 
5
®
 software. Values were considered statistically significant in all experiments when p<0.05. 154 
2.5. Fluorescence microscopy assays 155 
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HCT-15 (10000 cells/500µL/well) and RKO (50000 cells/500µL/well) cell lines were seeded 156 
on coverslips in 24-well plates and incubated at 37 ºC in a 5% CO2 atmosphere for 24 h. 157 
Spent media were removed, cells were washed with PBS 1x and then incubated with 0.025 158 
mg/mL of RhodamineB@NaY during 48 h. Cells were washed twice with PBS-Tween 0.05% 159 
(PBST 0.05%), fixed with cold methanol during 10 min, washed twice with PBST 0.05% and 160 
permeabilized with PBST 0.01% for 10 min. 161 
Next, and after two washes with PBST 0.05%, cells were blocked with FBS 10% in PBST 162 
0.05% during 30 min and then incubated with anti-β-tubulin antibody (ab6046, Abcam®) 163 
diluted in FBS 5% in PBST 0.05% (1:700) during 1 h at room temperature. In the next step, 164 
cells were washed three times with PBST 0.05% (10 min each) and incubated with the 165 
secondary antibody anti-rabbit Alexa Fluor 488 (A11008, Invitrogen) diluted in FBS 5% in 166 
PBST 0.05% (1:1000) during 1 h at room temperature. Finally, after three washes with PBST 167 
0.05% (10 min each) and one wash with PBS (5 min), cells were mounted in Vectashield 168 
mounting media with 4',6'-diamidino-2'-phenylindole (DAPI) (Vector Laboratories). Images 169 
were acquired in an Olympus IX81 fluorescence microscope (Tokyo, Japan), using Cell P 170 
software. 171 
2.6. Characterization methods  172 
The textural characterization of the zeolites was based on the N2 adsorption isotherms, 173 
determined at -196 ºC with a Quantachrome NOVA 4200e apparatus. The samples were 174 
previously outgassed at 150 ºC under vacuum. The micropore volumes (Vmicro) and mesopore 175 
surface areas (Smeso) were calculated by the t-method. Surface areas were calculated by 176 
applying the BET equation. Mesoporous size distributions were obtained from the desorption 177 
branch of the isotherm using the Barrett, Joyner and Halenda (BJH) method [37].
 
Elemental 178 
analyses of carbon, nitrogen, and hydrogen were carried out on a LECO CHNS-932 179 
equipment. Scanning electron micrographs (SEM) were collected on a LEICA Cambridge 180 
S360 Scanning Microscope equipped with an EDX system for NaY and 5-FU@NaY. The 181 
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morphology of NanoNaY, 5-FU@NanoNaY, LTL and 5-FU@LTL was studied by scanning 182 
electron microscopy using a NanoSEM–FEI Nova 200 (FEG/SEM) equipped with an EDX 183 
system. In order to avoid surface charging, samples were coated with gold in vacuum prior to 184 
analysis, by using a Fisons Instruments SC502 sputter coater. 
1
H-
13
C cross-polarization/magic 185 
angle spinning nuclear magnetic resonance (
13
C-CP/MAS NMR) and MAS 
27
Al spectra were 186 
recorded on a 9.4 T wide-bore (400 MHz, 
1
H Larmor frequency) Bruker Avance III 187 
spectrometer. A 4 mm double-resonance MAS probe was employed at 100.6 MHz (
13
C) and 188 
104.2 MHz (
27
Al) Larmor frequencies. Samples were spun in ZrO2 rotors using a spinning 189 
rate of 10 and 14 kHz, respectively for 
13
C and 
27
Al experiments. 
13
C-CP/MAS NMR spectra 190 
were recorded using a ramp step (varying from 100% to 50% in amplitude using 100 points); 191 
contact time: 3.0 ms; 
1
H 90° excitation pulse: 2.5 μs; 1H and 13C radio-frequency field 192 
strengths for CP were set to 87 kHz and 68 kHz, respectively; recycle delay: 5 s. TPPM-15 193 
decoupling was employed during the signal acquisition using a 4.75 μs pulse length for the 194 
basic TPPM pulse unit along the 
1
H channel, employing a 
1
H radio-frequency field strength of 195 
100 kHz. 
27
Al spectra were recorded with an excitation pulse length of 0.7 μs (corresponding 196 
to 10º flip angle) and 1 s recycle delay. The release studies were carried out by high 197 
performance liquid chromatography (HPLC – JASCO 980-PU) using an isocratic pump and a 198 
double on line detection including an UV–vis detector and refractometer. A LiChroCart 250-4 199 
RP-18e/5 µm column from Merck with a mobile phase contained a phosphate solution (0.01 200 
M) in methanol/water (60/40) were used for the HPLC assays. The flow rate was 0.4 mL/min 201 
and the injection volume was 20 µL and the absorbance of 5-FU was monitored at 260 nm. 202 
Calibration curve was constructed using solutions of 5-FU with concentrations from 0.0005 203 
mg/mL to 0.10 mg/mL. Room temperature Fourier Transform Infrared (FTIR) spectra of the 204 
samples in KBr pellets were measured using a Bomem MB104 spectrometer in the range 205 
4000-500 cm
-1
 by averaging 20 scans at a maximum resolution of 4 cm
-1
. The loading and the 206 
thermal stability of the samples were determined by thermogravimetric analysis in a STA 409 207 
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PC/4/H Luxx Netzsch thermal analyser. The atmosphere used was high purity air (99.99 % 208 
minimum purity) with a flow rate of 50 cm
3
/min. The sample holders used were crucibles of 209 
alumina oxide, supplied by Netzsch. The samples were heated between 50 and 700 ºC at 10 210 
ºC/min to evaluate the thermal stability. 211 
 212 
3. Results and discussion  213 
3.1. Loading and Physicochemical Characterization of DDS 214 
The method for the preparation of the DDS was the adsorption of 5-FU in liquid phase within 215 
the zeolite pores and channels [30,31] and the resulting DDS were characterized by several 216 
techniques.  217 
Loading of 5-FU into the zeolites was determined by thermogravimetric analysis (TGA). All 218 
DDS present the same weight loss in the studied temperature range. Two distinct weight 219 
changes are seen in the TGA data for pure 5-FU around 200-305 ºC and 305-410 ºC, which 220 
can be attributed to the onset of melting, followed by decomposition of the 5-FU molecule 221 
[38].
 
In the case of drug-loaded zeolites, the weight change is extended over the entire 222 
temperature range up to 700 ºC [39].
 
A small weight loss at 150 
o
C was also observed in the 223 
DDS, which can be attributed to the removal of physisorbed water in the zeolite [35,36]. The 224 
TGA curve for the parent zeolites shows the same weight loss around 120 ºC. The other 225 
weight changes observed in DDS were similar to the ones of 5-FU.  226 
Table 1 shows the 5-FU loading obtained for all prepared DDS. The drug loading studies 227 
revealed significant encapsulation efficiency for NaY followed by nanoNaY and LTL. Both 228 
nanosized zeolites, nanoNaY and LTL, show similar encapsulation efficiency, ca. 55 %. 229 
 230 
Table 1- Loading of 5-FU in the DDS. 231 
 232 
 10 
DDS 5-FU 
(mmol)
a
 
5-FU 
(mmol)
b
 
Yield 
(%)
c
 
5-FU@NaY 0.99 0.72 71.3 
5-FU@nanoNaY 0.99 0.55 55.6 
5-FU@LTL 0.99 0.52 52.5 
a
Initial 5-FU amount in the solution; 
b
5-FU loading in zeolite determined by TGA; 
c
Encapsulation 233 
efficiency of 5-FU in zeolites. 
 234 
 235 
NaY presents a larger micropore volume than the other zeolites, suggesting that this zeolite 236 
has a higher capacity for 5-FU loading, since it adsorbs preferentially on the micropores (see 237 
supplementary data). 238 
The release profiles of 5-FU from zeolites, NaY, nanoNaY and LTL are shown in Fig. 1. The 239 
results were similar, with maxima of 80%, 94% and 89% 5-FU release up to 48 h for NaY, 240 
nanoNaY and LTL, respectively. 241 
 242 
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Fig. 1. Release profiles of (a) 5-FU@NaY, (b) 5-FU@nanoNaY and (c) 5-FU@LTL. The 243 
insets correspond to the 5-FU release from the DDS up to 10 min. The release was 244 
measured in a phosphate buffer solution (PBS) at pH = 7.4 and 37 ºC. . where 245 
 [36] the number of moles at time t (corrected to account for changes in volume) 246 
and W is the weight (mg) of the zeolite.
 
247 
 248 
All three zeolites show similar initial burst rates of 5-FU release with an exponential-type 249 
behavior and ca. 80-90% 5-FU release in the initial 10 min. The similarity observed in the 5-250 
FU release profiles seems to be not dependent of the framework structure of the zeolites, 3D 251 
(Y zeolite) or 1D (LTL zeolite). The diffusion from within the zeolite pores and channels 252 
appears to be no different from the internal surface or even from the aggregate of particles.  253 
In order to establish the best release profile, the DDS release kinetic profiles were modeled by 254 
fitting the mathematical kinetic models usually used to describe in vitro drug dissolution and 255 
release from pharmaceutical dosage forms [40],
 
including the zero-order (Qt = Q0+K0t), first-256 
order (lnQt = lnQ0 +Ktt), Higuchi (Qt = KH√t), Hixson-Crowell (Q0
1/3
-Qt
1/3 
= Kst), Korsmeyer-257 
Peppas (Qt/Q∞ = Kkt
n
) and Weibull (log[-ln(1-(Qt/Q∞))] = blogt-loga) models [40].
 
The release 258 
models with major application and best describing drug release are the zero-order, Higuchi, 259 
Korsmeyer-Peppas and Weibull models [40,41]. The fitted data for the selected release kinetic 260 
models are listed in Table 2.  261 
5.00
3.75
2.50
1.25
0
0 8 16 24 32 40 48
0 3 5 8 10
Q
t 
(x
1
0
-6
 m
o
l/
m
g
)
Q
t 
(x
1
0
-6
 m
o
l/
m
g
)
c)
5.0
3.3
1.7
t (min)
t (h)
 12 
Table 2- Fitted parameters of the kinetic models used in the in vitro drug release of DDS. 262 
Mathematical 
models 
5-FU@NaY 5-FU@nanoNaY 5-FU@LTL 
Zero order 
K0 (h
-1
) 
R 
 
41.5x10
-6
 
0.4416 
 
1.2x10
-6
 
0.6567 
 
2.5x10
-6
 
0.5475 
Higuchi 
KH (h
-1/2
) 
R 
 
6.6x10
-6
 
0.5943 
 
1.2x10
-6
 
0.7806 
 
2.6x10
-6
 
0.6657 
Korsmeyer-
Peppas 
Kp (h
-n
) 
n 
R 
 
 
1.04 
0.03 
0.8361 
 
 
1.06 
0.05 
0.9111 
 
 
1.25 
0.17 
0.8304 
Weibull 
Ti (h) 
b 
a 
R 
 
0.002 
0.37 
0.09 
0.9975 
 
0.001 
0.30 
0.13 
0.9851 
 
0.010 
0.51 
0.10 
0.8988 
K0, KH and Kp are the release rate constants; n is the release exponent; Ti is the time parameter (time 263 
interval necessary to release 50% to 90% of the drug); b is the shape parameter and a is the scale 264 
parameter. 265 
 266 
The in vitro drug release from zeolites was best described by the Weibull model, as the plots 267 
showed the highest linearity. The Weibull model is more useful for comparing the release 268 
profiles of matrix-type drug delivery [41]. This model describes the dissolution curve in terms 269 
of applicable parameters and is able to empirically describe, but not mechanistically 270 
characterize, the dissolution behavior of the dosage form. The advantage of the Weibull 271 
model lies on its ability to fit almost any kind of dissolution curve and it is, therefore, often 272 
used to describe experimental data, especially when the mechanism of release underlying the 273 
dissolution behavior is unknown [42]. In this model, the shape parameter, b, characterizes the 274 
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curve as exponential (b=1, case 1), sigmoid, S-shaped, with upward curvature followed by a 275 
turning point (b>1, case 2), or parabolic, with a higher initial slope and after that consistent 276 
with the exponential (b<1, case 3) [40-42].
 
The b parameter obtained after fitting the release 277 
data was 0.37, 0.30 and 0.51 for 5-FU@NaY, 5-FU@nanoNaY and 5-FU@LTL, respectively. 278 
These values are consistent with case 3 exhibiting higher initial slope followed by an 279 
exponential curvature, as it is evident from the release profiles for all DDS in Fig. 1.  280 
The rapid release of 5-FU from zeolites may be rationalized in terms of the size of the drug 281 
and its interactions with the zeolite frameworks. 5-FU is a small molecule with molecular 282 
dimensions 4.936 Å x 5.387 Å x 5.043 Å, which can easily diffuse out of the micropores of 283 
faujasite and Linde type L. These zeolite structures have similar pore opening diameters, 284 
which results in the enhanced release of the drug in the buffer solution.  285 
The 
13
C NMR spectrum of 5-FU shows the characteristic peaks of the drug molecule with 286 
resonances at 13C = 161.6 (C4), 149.5 (C2), 139.3 (C5) and 130.0 (C6) ppm, consistent with 287 
previous assignments [43]. The presence of the 5-FU C2, C5 and C6 peaks in the 
13
C 288 
CP/MAS spectrum of 5FU@NaY indicates both, the presence and integrity of the drug, and 289 
minimal interactions with the zeolite framework (see supplementary data). The poor signal-to-290 
noise ratio of this spectrum (despite 22 h of acquisition) does not allow confirmation of the 291 
presence of the C4 resonance, whose observation may also be hindered by longer 
1
H 292 
relaxation. 
27
Al solid-state MAS NMR spectra of all samples are identical showing that the 293 
experimental procedure used does not damage the structure of the zeolites and providing no 294 
evidence for significant framework-drug interactions. 
 
295 
Fourier Transformed Infrared spectroscopy (FTIR) also does not reveal any significant 296 
interactions between the drug and the zeolite (see supplementary data). The 5-FU spectrum 297 
shows the characteristic vibrational modes of the anticancer molecule. The bands at 1722, 298 
1660 and 1246 cm
-1
 are attributed to the cyclic imide, CO-NH-CO. The bands at 1430 cm
-1
 299 
are attributed to C–H stretching in –CF=CH– and the C–H deformation vibration band in –300 
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CF=CH– is observed at 814 cm-1 [4,7,44]. In the region 2750-3200 cm-1, the vibrational 301 
stretching modes from C–H and N–H were also observed [7]. 302 
For the prepared DDS, the FTIR spectra are dominated by the strong bands assigned to the 303 
vibrational modes arising from the zeolite structure. The presence of physisorbed water is 304 
detected by the (O-H) stretching vibration at 3410 cm
-1
 and the (O-H) deformation band at 305 
1635 cm
-1
. The bands corresponding to the lattice vibrations are observed in the spectral 306 
region between 1300 and 450 cm
-1
 [25,31]. No shift or broadening in the principal zeolite 307 
vibrational bands occur upon inclusion of the drug, further substantiating that the zeolite 308 
frameworks remain unchanged. The spectra of the DDS display the bands attributed to 5-FU, 309 
with no measurable shifts indicating that the drug is present and not interacting strongly with 310 
the zeolitic frameworks.  311 
 312 
3.2- Drug bioactivity studies 313 
The cytotoxicity studies were carried out in two different cancer cell lines, HCT-15 and RKO. 314 
These lines are well characterized human colorectal carcinoma cells, with different 315 
phenotypes and genetic backgrounds. These cells were chosen as predictive models to test the 316 
potentiation of the chemotherapeutic agent 5-FU into the zeolites NaY, nanoNaY and LTL. 317 
Viability of HCT-15 and RKO cells was evaluated by the sulforhodamine B (SRB) assay, 318 
which measures the drug-induced cytotoxicity and cell proliferation, used for large-scale 319 
drug-screening applications [45]. 320 
The drug bioactivity studies were performed by preparing five working DDS concentrations, 321 
by diluting a stock suspension (1.0 mg/mL) in culture medium. For better homogenization, all 322 
suspensions were submitted to ultrasonic dispersion for 2 min prior to use. This procedure 323 
was optimized in our previous work [31].  324 
The cytotoxicity of the starting zeolites, NaY, nanoNaY and LTL, was investigated in HCT-325 
15 and RKO cell lines to assess their suitability as DDS. In both cell lines, all zeolites gave 326 
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similar results according to our previous work, showing no significant toxicity [31]. Fig. 2 327 
and 3 show the effects on cell viability obtained when treating HCT-15 and RKO cells with 328 
the non-encapsulated 5-FU and 5-FU@zeolite systems, when taking into consideration the 329 
amount of drug present in the DDS systems for the different suspensions used.  330 
 (a) 
 
 
(b) 
 
 
(c) 
 
 
Fig. 2. Effect of NaY (a), nanoNaY (b) and LTL (c) zeolites and DDS systems on HCT-15 331 
colon carcinoma cell viability. HCT-15 cell line was incubated with zeolites and 332 
different DDS concentrations for 48 h. Cell viability was measured by SRB assay. 333 
Values are means ± SD of three independent experiments, each performed in 334 
triplicate. ***p<0.001 compared to zeolite alone. 335 
 336 
(a)  
 
(b) 
 
(c) 
 
 
Fig. 3. Effect of NaY (a), nanoNaY (b) and LTL (c) zeolites and DDS systems on RKO colon 337 
carcinoma cell viability. RKO cell line was incubated with zeolites and different DDS 338 
concentrations for 48 h. Cell viability was measured by SRB assay. Values are means 339 
nanoNaY 
LTL 
5-FU@LTL 5-FU@nanoNaY 
NaY 
5-FU@NaY 
NaY 
5-FU@NaY 
nanoNaY 
5-FU@nanoNaY 
LTL 
5-FU@LTL 
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± SD of three independent experiments, each performed in triplicate. *p<0.05, 340 
***p<0.001 compared to zeolite alone. 341 
 342 
The differences between controls (without zeolite) and the range of zeolite concentrations are 343 
non-significant, showing in this way that all zeolites are non-toxic to the cells for the selected 344 
period of incubation and concentrations. Compared to zeolites alone (control), there is an 345 
evident reduction in cell viability, with increasing concentrations of 5-FU in the zeolite 346 
system for both cell lines. For HCT-15 cell line, 5-FU encapsulated into NaY, nanoNaY and 347 
LTL, led to a reduction in cell viability from 64 to 34%, 66 to 43% and 67 to 46% comparing 348 
with cells treated with the starting zeolite. In RKO cells (Fig. 3), incubation of the 5-349 
FU@zeolite systems resulted also in a significant decrease in cell viability for the three 350 
zeolite systems: from 58 to 27% for 5-FU@NaY, 80 to 29% for 5-FU@nanoNaY and 54 to 351 
28% for 5-FU encapsulated in LTL zeolite. Moreover, the reduction in viability was more 352 
pronounced in RKO cell line. 353 
5-FU working concentrations (0.01, 0.10, 1 and 10 mM) were obtained by diluting the stock 354 
solution (1 M) in culture medium. It is possible to observe a dose-dependent decrease in cell 355 
viability, being the IC50 values of 0.61 mM for HCT-15 cells and 0.13 mM for RKO (Table 356 
3). 357 
Table 3- 5-FU, 5-FU@NaY, 5-FU@nanoNaY and 5-FU@LTL IC50 values for HCT-15 and 358 
RKO cell lines. 359 
 
HCT-15 
IC50 (mM)    Potentiation 
RKO 
IC50 (mM)    Potentiation 
5-FU 0.61 -- 0.13 -- 
5-FU@NaY 0.08 7.6 0.03 4.3 
5-FU@nanoNaY 0.21 2.9 0.08 1.6 
5-FU@LTL 0.31 1.9 0.03 4.3 
 360 
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By comparing the results obtained when treating cells with the non-encapsulated 5-FU with 361 
the encapsulated 5-FU, there is an obvious potentiation of the effect of the drug. For HCT-15, 362 
there is an increase in efficiency of the drug between 1.9 and 7.6-fold, corresponding to 5-FU 363 
assay concentrations of 0.08 and 0.31 mM, respectively. Likewise, treatment of RKO cells 364 
with the encapsulated 5-FU resulted in a potentiation of the effect of the drug from 1.6 to 4.3 365 
fold.  366 
For HCT-15 cells, NaY DDS was more effective than the two remaining nanosized DDS, 367 
probably due to the higher 5-FU loading in zeolite Y. For RKO cells, both NaY and LTL 368 
DDS show the same potentiation. In this case, particle size could have justified the similar 369 
potentiation. However, the different potentiation obtained with LTL in the two cell lines is not 370 
clear, warranting further studies. For higher concentrations of the DDS or starting zeolites 371 
(above 0.25 mg/mL), cell viability began to be affected, likely due to the compromise of cell-372 
nutrient exchange with the culture media [30,31]. 373 
In order to assess the interaction between the zeolites and the CRC cells, fluorescence 374 
microscopy assays were performed. Fig. 4 shows the results where HCT-15 and RKO cells 375 
were treated with the NaY zeolite loaded with the fluorescent compound Rhodamine B. 376 
Comparing the control images with those with RhodamineB@NaY, it is possible to observe 377 
that the zeolite is able to enter the cell cytoplasm. Although this approach was only applied to 378 
NaY zeolite, it is expected that both nanoNaY and LTL zeolites are also able to enter the cells 379 
due to their smaller dimensions, where internalization would be even easier. Extrapolating 380 
these results for the DDS, it is likely that the drug release is achieved inside the cells if the 381 
DDS is put in contact with them.  382 
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 383 
 384 
Fig. 4. Fluorescence microscopy images showing the cellular localization of NaY zeolite 385 
loaded with Rhodamine B in CRC cell lines (red, arrows). HCT-15 cell line: (a)-(d); 386 
RKO cell line: (e)-(h); Control: (a), (e) and (f); RB@NaY: (b), (c), (d), (g) and (h). 387 
Nucleus/DAPI (blue), β-tubulin/FITC (green), RB@NaY/TRITC (red); 200x (e); 400x 388 
(a) and (f); 600x (b); 1000x (c), (d), (g) and (h). 389 
a) 
 
 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
c) 
 
 
 
 
 
 
 
 
 
d) 
 
 
 
 
 
 
 
e) 
 
 
 
 
 
 
 
 
 
f) 
 
 
 
 
 
 
 
g) 
 
 
 
 
 
 
 
 
 
h) 
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 390 
By encapsulating 5-FU into zeolites, we increased significantly the efficiency of this drug. 391 
We believe that similarly to other systems [16, 46-48], the zeolite DDS allow the release of 5-392 
FU, increasing the bioavailability of the drug, and thus explaining the increase in potency. 393 
Moreover, the entry of 5-FU into the cells could also contribute to the high increase in 394 
potency observed. Thus, this potency rise could be the combined result of both the increase in 395 
5-FU bioavailability and the facilitation of 5-FU entry into the cell by the DDS. 396 
 397 
4- Conclusions 398 
5-FU was successfully loaded into the zeolite structures with different particle sizes, NaY 399 
(700 nm) and two nanosized zeolites, nanoNaY (150 nm) and nanoLTL (80 nm) and the 400 
loading of 5-FU was found to be highest in NaY followed by nanoNaY and LTL. FTIR and 401 
solid-state NMR (
13
C and 
27
Al) provided no evidence for significant framework-drug 402 
interactions. The release of the drug from the zeolite structures in buffer solution at pH = 7.4 403 
and 37 °C followed the Weibull model.
 
The effect of the zeolites and DDS on HCT-15 and 404 
RKO human colon carcinoma cell lines viability was evaluated. DDS based on zeolites were 405 
able to increase the efficiency of 5-FU, a widely used anticancer drug. We believe these 406 
systems should be further explored in other cancer models, e.g. in vivo models, to confirm the 407 
efficiency of the systems. 408 
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